Short answer · Medically reviewed summary · Last updated: 2026-04-06
Scleroderma, derived from the Greek words "skleros" (hard) and "derma" (skin), was first clinically described in the medical literature by Italian physician Carlo Curzio in 1752, who documented a case of a woman with hardened, leathery skin. The Evolution of Clinical Understanding Following Curzio’s initial report, the medical community began to distinguish between localized forms of the disease and the more systemic, life-threatening manifestations. In 1836, Giovanni Battista Fantonetti coined the term "scleroderma" to describe the condition's primary clinical feature.
1 people with Scleroderma have shared their first-person experience on this question at DiseaseMaps.
What is the history of Scleroderma?
History of Scleroderma: when and how it was discovered, and the milestones in research since, medically reviewed.
Scleroderma, derived from the Greek words "skleros" (hard) and "derma" (skin), was first clinically described in the medical literature by Italian physician Carlo Curzio in 1752, who documented a case of a woman with hardened, leathery skin.
The Evolution of Clinical Understanding
Following Curzio’s initial report, the medical community began to distinguish between localized forms of the disease and the more systemic, life-threatening manifestations. In 1836, Giovanni Battista Fantonetti coined the term "scleroderma" to describe the condition's primary clinical feature. By the late 19th century, Sir William Osler provided one of the most comprehensive early accounts of Scleroderma, recognizing it as a systemic disorder that could affect internal organs, not just the skin. For decades, the disease was often misdiagnosed or confused with other connective tissue disorders, such as lupus or rheumatoid arthritis, due to overlapping symptoms.
Milestones in Science and Advocacy
The 20th century marked significant shifts in our approach to Scleroderma. The discovery of the CREST syndrome variant in the 1960s helped clinicians better categorize the disease’s progression. Treatment evolved from rudimentary efforts to soften the skin to modern, targeted therapies that address vascular complications and pulmonary fibrosis. Historically, patients were often told their condition was purely psychological or incurable, leading to profound isolation; however, the rise of global patient advocacy groups in the 1970s and 80s transformed Scleroderma from a "hidden" disease into a focused area of research.
Modern Insights
Today, our understanding of Scleroderma has been revolutionized by genomic studies and molecular biology. We now understand that it is an autoimmune-mediated fibrotic disease involving complex interactions between the immune system, vascular endothelium, and fibroblasts. Advanced imaging and biomarker research now allow us to detect internal organ involvement far earlier than in the past, drastically improving the quality of life for those living with this condition.
Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: The portal for rare diseases and orphan drugs
- Scleroderma Foundation: History and Research Initiatives
- OMIM (Online Mendelian Inheritance in Man)
Posted Mar 30, 2018 by Amy 2600
